title: [A Woman Experienced Severe Thrombocytopenia When Treated With Fluvastatin].
abstract: A 62-year-old woman treated with fluvastatin experienced three separate thrombocytopenic illnesses, severe on two occasions associated with nadir platelet count of 57 000/µL and 75 000/µL. The hospital pharmacist replaced fluvastatin by pravastatin during three stays. Platelet count has increased some days after this substitution. These results suggest that fluvastatin could be involved in these thrombocytopenic episodes.
authors.affiliation: Service de Pharmacie, Centre Hospitalier de Lunéville, Lunéville, France.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Potier
authors.affiliation: Service de Pharmacie, Centre Hospitalier de Lunéville, Lunéville, France.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Dony
authors.affiliation: Service de Cardiologie, Centre Hospitalier de Lunéville, Lunéville, France.
authors.forename: Aline
authors.initials: A
authors.lastname: Crapsky
authors.affiliation: Service de Cardiologie, Centre Hospitalier de Lunéville, Lunéville, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Ferry
authors.affiliation: Service de Pharmacie, Centre Hospitalier de Lunéville, Lunéville, France.
authors.forename: David
authors.initials: D
authors.lastname: Piney
authors.affiliation: Service de Pharmacie, Centre Hospitalier de Lunéville, Lunéville, France.
authors.forename: Edith
authors.initials: E
authors.lastname: Dufay
mesh_terms: D000082:Acetaminophen / Q000008:administration & dosage / Q000627:therapeutic use; D001667:Binding, Competitive; D015897:Comorbidity; D065729:Cytochrome P-450 CYP2C9 / Q000378:metabolism; D065688:Cytochrome P-450 CYP2C9 Inhibitors / Q000493:pharmacokinetics; D057915:Drug Substitution; D004357:Drug Synergism; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D000077340:Fluvastatin; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008658:Inactivation, Metabolic / Q000187:drug effects; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use; D012008:Recurrence; D013921:Thrombocytopenia / Q000139:chemically induced*; D014635:Valproic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D065688:Cytochrome P-450 CYP2C9 Inhibitors; D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D000082:Acetaminophen; D000077340:Fluvastatin; D014635:Valproic Acid; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D017035:Pravastatin